Skip to content

Wall Street can wait: Why one U.S. biotech firm is listing in Hong Kong first

Business

Global biotech firms are increasingly being drawn to Hong Kong for its growing investor base and proximity to Chinese pharmaceutical partners.


Source: CNBC Top News — This article was automatically imported from the source. Read full article at original source →

CN
Originally published by CNBC Top News cnbc.com
Visit original article

admin

Leave a Comment